Effects of Combination Treatment of Intravesical Resiniferatoxin Instillation and Hydrodistention in Patients with Refractory Painful Bladder Syndrome/Interstitial Cystitis: A Pilot Study
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: Painful bladder syndrome/interstitial cystitis (PBS/IC) is a disabling disease of the urinary bladder, and its etiology and treatment are not yet established. Current medications used in the treatment of PBS/IC have shown limited efficacy. This prospective study investigated the efficacy of intravesical resiniferatoxin (RTX) in PBS/IC refractory to medical treatment. Methods: Patients with proven PBS/IC refractory to traditional medical treatment were enrolled. By randomized trial, a total of 18 consecutive patients were divided into two groups: treatment with hydrodistention and intravesical RTX (group 1) or treatment with hydrodistension only (group 2). We assessed bladder pain by use of a visual analogue pain scale, the maximal urine flow rate, post-void residual urine volume , and a voiding diary before and 3 months after treatment. Results: The median age of the 18 patients was 55.8±6.9 years, and the median duration of symptoms before diagnosis was 3.6±1.6 years. Frequency, functional bladder capacity, and score on a 5-point pain scale were significantly improved at 3-month after treatment in both groups. Intravesical RTX instillation plus hydrodistention, compared with hydrodistention only, did not have a significant effect on the voiding symptoms or uroflowmetry of the patients but significantly improved scores on the pain scale. Conclusions: Intravesical RTX instillation plus hydrodistention was effective in relieving pain but was not effective in improving lower urinary tract symptoms. Further larger studies are needed to clarify the efficacy of combination treatment of intravesical RTX instillation and hydrodistention.
Abstract
Purpose: Painful bladder syndrome/interstitial cystitis (PBS/IC) is a disabling disease of the urinary bladder, and its etiology and treatment are not yet established. Current medications used in the treatment of PBS/IC have shown limited efficacy. This prospective study investigated the efficacy of intravesical resiniferatoxin (RTX) in PBS/IC refractory to medical treatment. Methods: Patients with proven PBS/IC refractory to traditional medical treatment were enrolled. By randomized trial, a total of 18 consecutive patients were divided into two groups: treatment with hydrodistention and intravesical RTX (group 1) or treatment with hydrodistension only (group 2). We assessed bladder pain by use of a visual analogue pain scale, the maximal urine flow rate, post-void residual urine volume , and a voiding diary before and 3 months after treatment. Results: The median age of the 18 patients was 55.8±6.9 years, and the median duration of symptoms before diagnosis was 3.6±1.6 years. Frequency, functional bladder capacity, and score on a 5-point pain scale were significantly improved at 3-month after treatment in both groups. Intravesical RTX instillation plus hydrodistention, compared with hydrodistention only, did not have a significant effect on the voiding symptoms or uroflowmetry of the patients but significantly improved scores on the pain scale. Conclusions: Intravesical RTX instillation plus hydrodistention was effective in relieving pain but was not effective in improving lower urinary tract symptoms. Further larger studies are needed to clarify the efficacy of combination treatment of intravesical RTX instillation and hydrodistention.
참고문헌 (19)
- Hanash KA, "Interstitial cystitis in men", J Urol, 102, pp.427~428 (1969)
- Gillenwater JY, "Summary of the National Institute of Arthritis, Diabetes, Digestive and Kidney Diseases Workshop on Interstitial Cystitis, National Institutes of Health, Bethesda, Maryland, August 28-29, 1987", J Urol, 140, pp.203~206 (1988)
- van de Merwe JP, "Diagnostic criteria, classification, and nomenclature for painful bladder syndrome", interstitial cystitis: an ESSIC proposal, 2008, pp.53, 60~67
- Hanno P, "Bladder Pain Syndrome Committee of the International Consultation on Incontinence", Neurourol Urodyn, 29, pp.191~198 (2010)
- Cole EE, "Are patient symptoms predictive of the diagnostic and", or therapeutic value of hydrodistention?, 2005, pp.24, 638~642
- Theoharides TC, "Treatment approaches for painful bladder syndrome", interstitial cystitis, 2007, pp.67, 215~235
- Kusek JW, "The epidemiology of interstitial cystitis: is it time to expand our definition?", Urology, 57(6 Suppl 1), pp.95~99 (2001)
- Nickel JC, "Psychosocial phenotyping in women with interstitial cystitis", painful bladder syndrome: a case control study, 2010, pp.183, 167~172
- Franksson C, "Interstitial cystitis: a clinical study of fifty-nine cases", Acta Chir Scand, 113, pp.51~62 (1957)
- Ottem DP, "What is the value of cystoscopy with hydrodistension for interstitial cystitis?", Urology, 66, pp.494~499 (2005)
- Hanno PM, "AUA guideline for the diagnosis and treatment of interstitial cystitis", bladder pain syndrome, 2011, pp.185, 2162~2170
- Lazzeri M, "Intravesical capsaicin for treatment of severe bladder pain: a randomized placebo controlled study", J Urol, 156, pp.947~952 (1996)
- Apostolidis A, "Effect of intravesical Resin iferatoxin (RTX) on lower urinary tract symptoms, urodynamic parameters, and quality of life of patients with urodynamic increased bladder sensation", Eur Urol, 50, pp.1299~1305 (2006)
- Lazzeri M, "Intravesical resiniferatoxin for the treatment of hypersensitive disorder: a randomized placebo controlled", J Urol, 164(3), pp.676~679 (2000)
- Chen TY, "Prospective, randomized, double-blind study of safety and tolerability of intravesical resiniferatoxin (RTX) in interstitial cystitis (IC)", Int Urogynecol J Pelvic Floor Dysfunct, 16, pp.293~297 (2005)
- Payne CK, "Intravesical resiniferatoxin for the treatment of interstitial cystitis: a randomized, double-blind, placebo controlled trial", J Urol, 173, pp.1590~1594 (2005)
- Silva C, "The effect of intravesical resiniferatoxin in patients with idiopathic detrusor instability suggests that involuntary detrusor contractions are triggered by C-fiber input", J Urol, 168, pp.575~579 (2002)
- Rios LA, "Intravesical resiniferatoxin for the treatment of women with idiopathic detrusor overactivity and urgency incontinence: a single dose, 4 weeks, double-blind, randomized, placebo controlled trial", Neurourol Urodyn, 26, pp.773~778 (2007)
- Peng CH, "Multiple intravesical instillations of low-dose resiniferatoxin in the treatment of refractory interstitial cystitis", Urol Int, 78, pp.78~81 (2007)